OncoMatch

OncoMatch/Clinical Trials/NCT05674305

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Is NCT05674305 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Radiotherapy and Cisplatin for nasopharyngeal carcinoma.

Phase 3RecruitingFudan UniversityNCT05674305Data as of May 2026

Treatment: Radiotherapy · Cisplatin — The goal of this multicenter randomized non-inferior study is to compare radiotherapy alone versus concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients whose EBV DNA drop to undetectable level after one cycle neoadjuvant chemotherapy using GP regimen. The main question it aims to answer is: the omission of concurrent chemotherapy is safe in the relatively good prognostic patients identified by the response of EBV DNA. Participants will be randomized to either radiotherapy alone or the standard treatment concurrent chemoradiotherapy if their EBV DNA decrease to undetectable level post first cycle of neoadjuvant chemotherapy and don't rebound in the second and third cycle.

Check if I qualify

Extracted eligibility criteria

Cancer type

Head and Neck Squamous Cell Carcinoma

Disease stage

Required: Stage III, IVA

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: radiotherapy

Cannot have received: chemotherapy

Cannot have received: targeted therapy

Lab requirements

Blood counts

HGB ≥90 g/L, WBC ≥4×10^9 /L, PLT ≥100×10^9 /L

Kidney function

serum creatinine <1x ULN

Liver function

ALT, AST < 1.5x ULN; total bilirubin <1.0x ULN

Hemoglobin (HGB) ≥90 g/L, white blood cell (WBC) ≥4×10^9 /L, platelet (PLT) ≥100×10^9 /L. Liver function: ALT, AST < 1.5x ULN, total bilirubin <1.0x ULN. Renal function: serum creatinine <1x ULN.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify